JGC
AGIO icon

J. Goldman & Co’s Agios Pharmaceuticals AGIO Stock Holding History

J. Goldman & Co’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13,500
Closed -$301K – 403
2023
Q4 		$301K Hold
13,500
– – 0.01% 284
2023
Q3 		$334K Sell
13,500
-6,800
-33% -$180K 0.01% 301
2023
Q2 		$575K Buy
+20,300
New +$505K 0.02% 286

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

J. Goldman & Co's AGIO Position: Q3 2017 in Review

J. Goldman & Co sold out of Agios Pharmaceuticals (AGIO) in Q3 2017, closing a stake of 58,800 shares — an estimated $3.02M sold.

J. Goldman & Co first reported a position in AGIO in Q2 2017 and held it in 1 quarter. The position peaked at $3.02M in Q2 2017. 171 funds tracked by Wall St. Rank hold AGIO as of Q3 2017.

  • J. Goldman & Co reported no remaining Agios Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • J. Goldman & Co sold 58,800 Agios Pharmaceuticals shares in Q3 2017, an estimated $3.02M.
  • J. Goldman & Co first reported a position in Agios Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • J. Goldman & Co's Agios Pharmaceuticals position peaked at $3.02M in Q2 2017.
  • 171 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2017.

Based on J. Goldman & Co's 13F filing for Q3 2017, filed 14 Nov 2017.